Table 4:

Cumulative incidence of recurrence. Proportional hazard frailty models for the subdistribution on R0 patients (N = 1325)

	HR (95% CI)a	P
Age (continuous, per 5 years increase)	0.91 (0.84–1.00)	0.039
Male	0.81 (0.55–1.19)	0.286
Myasthenia gravis	0.57 (0.33–0.98)	0.042
T size (continuous, per 1 cm increase)	1.16 (1.09–1.24)	0.003
Masaoka stage
1 (Ref)	1	–
2	1.46 (0.72–2.95)	0.288
3	5.67 (2.80–11.45)	<0.001
4	13.08 (5.70–30.03)	<0.001
Diagnosis
Thymoma WHO A-AB-B1 (Ref)	1	–
Thymoma WHO B2-B3	1.22 (0.67–2.20)	0.515
NETT	7.18 (3.48–14.82)	<0.001
Thymic carcinoma	1.50 (0.64–3.49)	0.349
Year of intervention
1990–1995 (Ref)	1	–
1996–2001	9.43 (2.82–31.51)	<0.001
2002–2007	10.92 (3.32–35.92)	<0.001
2008–2011	8.18 (1.49–44.77)	0.015
Mean number patients (yearly) treated yearly by centre
≤4 (Ref)	1	–
5–9	1.01 (0.41–2.46)	0.984
≥10	1.08 (0.56–2.09)	0.820

NETT: neuroendocrine thymic tumour.

^aAll effects were unadjusted for T size, whereas T size effect was unadjusted for Masaoka stage.